menu
    • menu

    Company profile for Sichuan Kelun-Biotech Biopharmaceutical

    NEW Drugs in Dev: 17
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. focuses on research, development, and manufacturing of biopharmaceutical products. With expertise in innovative drug development, clinical trials, and large-scale manufacturing, Kelun-Biotech aims to provide advanced therapeutic solutions. Their platforms support new drug research, quality manufacturing, and global commercialization.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sichuan Kelun-Biotech BiopharmaceuticalChina Flag
    Country
    Country
    China
    Address
    Address
    No. 666 Xinhua Avenue Chengdu Cross-Strait Science and Technology Industry Dev...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://en.kelun-biotech.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kelun-Bio Shares First-in-Human Data for B7-H3 ADC at ASCO 2026
    Kelun-Bio Shares First-in-Human Data for B7-H3 ADC at ASCO 2026

    02 Jun 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kelun-biotech-presents-first-in-human-study-data-for-its-novel-b7-h3-adc-skb500-at-asco-2026-302788517.html

    PR NEWSWIRE
    02 Jun 2026
    Share Share
    Kelun-Merck ADC Improves Survival in First-Line Lung Cancer
    Kelun-Merck ADC Improves Survival in First-Line Lung Cancer

    01 Jun 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/asco-kelun-merck-adc-shines-with-differentiated-overall-survival-in-first-line-lung-cancer

    BIOSPACE
    01 Jun 2026
    Share Share
    Sac-TMT + Pembro for 1L PD-L1+ NSCLC Published in The Lancet
    Sac-TMT + Pembro for 1L PD-L1+ NSCLC Published in The Lancet

    31 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sacituzumab-tirumotecan-sac-tmt-in-combination-with-pembrolizumab-for-first-line-treatment-of-pd-l1-positive-nsclc-published-in-the-lancet-302786239.html

    PR NEWSWIRE
    31 May 2026
    Share Share
    Kelun-Biotech Presents Phase 2 Lunbotinib Data in RET NSCLC
    Kelun-Biotech Presents Phase 2 Lunbotinib Data in RET NSCLC

    30 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kelun-biotech-presents-pivotal-phase-ii-data-for-lunbotinib-fumarate-a400ep0031-in-ret-fusion-positive-nsclc-at-2026-asco-302786202.html

    PR NEWSWIRE
    30 May 2026
    Share Share
    Sac-TMT Phase 3 OptiTROP-Lung05 Data at ASCO; Published in Lancet
    Sac-TMT Phase 3 OptiTROP-Lung05 Data at ASCO; Published in Lancet

    30 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/the-results-of-phase-iii-optitrop-lung05-study-of-sacituzumab-tirumotecan-sac-tmt-presented-as-an-asco-oral-presentation-and-simultaneously-published-in-the-lancet-302786204.html

    PR NEWSWIRE
    30 May 2026
    Share Share
    Kelun, Merck's Lung Cancer Combo Boosts Late-Stage Survival
    Kelun, Merck's Lung Cancer Combo Boosts Late-Stage Survival

    22 May 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/kelun-mercks-lung-cancer-combo-improves-survival-late-stage-china-trial-2026-05-21/

    REUTERS
    22 May 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search